DSIP

DSIP Research Overview

DSIP is a nine-amino-acid peptide first isolated from rabbit blood in 1977 and named for its apparent ability to promote delta-wave sleep. It is studied for insomnia, stress, and pain, though the research picture is more mixed than the name suggests.

Also known as: Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, Emideltide

Background

DSIP was discovered by Marcel Monnier and Guido Schoenenberger in Switzerland, who found that blood from rabbits kept in slow-wave sleep by thalamic stimulation could induce similar sleep in recipient rabbits. The responsible nonapeptide was purified in 1977. It occurs naturally in the hypothalamus, pituitary, and other tissues, but no gene encoding it has ever been found, which remains an odd gap in its biology and has led some researchers to question its status as a true hormone.

Human studies in the 1980s were small and produced inconsistent results. Some found DSIP improved sleep onset and quality in insomniacs, while others found no sleep effect at all. More consistent were findings in chronic pain, where a series of intravenous infusions reduced pain scores, and in opioid and alcohol withdrawal, where it eased symptoms. DSIP also blunted stress-induced cortisol and ACTH release in some experiments. The literature dried up after that era, so modern users are working from 40-year-old data.

In animals DSIP is a modulator rather than a sedative. It normalizes disturbed sleep patterns without forcing sleep, reduces stress hormone spikes, has antioxidant effects, and may protect against seizures. This fits with user reports: most describe deeper, more restorative sleep rather than knockout sedation, and some describe nothing. Its short half-life and rapid breakdown by peptidases limit what an injected amount can do.

Mechanistic Profile

DSIP does not act like a hypnotic. It appears to modulate several systems at once, with the net effect of normalizing circadian and stress rhythms. It reduces release of corticotropin-releasing hormone and ACTH under stress, lowers cortisol, and influences the secretion of LH, GH, and somatostatin. In the brain it modulates GABAergic and glutamatergic activity, increases serotonin turnover, and affects opioid receptor signaling, which likely explains the pain and withdrawal results. It shows antioxidant activity and stabilizes mitochondrial function in stressed tissue. The sleep effect, where it occurs, is thought to result from this broad stress-dampening action rather than direct sedation, which is why DSIP tends to improve sleep quality more than sleep onset.

Reported Research Findings

• DSIP was isolated from cerebral venous blood of sleeping rabbits and induced delta-wave sleep when infused into recipients. (rodent)

• Small trials in chronic insomnia reported improved sleep efficiency and daytime performance, though other trials found no effect. (human pilot)

• Repeated intravenous DSIP reduced pain scores in subjects with chronic, severe pain episodes. (human pilot)

• DSIP eased withdrawal symptoms in subjects dependent on opioids or alcohol. (human pilot)

• DSIP blunted stress-induced cortisol and ACTH release in animals and humans. (human pilot)

Analytical Validation, Formulation and Storage

• Purity: 99% or higher as verified by HPLC, with a third-party certificate of analysis available per batch.

• Formulation: lyophilised (freeze-dried) powder in a sterile sealed glass vial, to be reconstituted with an appropriate solvent for laboratory use.

• Reported half-life: About 15 minutes in plasma (estimated); rapidly degraded by peptidases.

• Storage: keep lyophilised material cool, dark and dry (long-term at or below -20 °C). Store reconstituted solutions refrigerated, avoid repeated freeze-thaw cycles and use within laboratory-defined windows.

Selected Literature

• Characterization of a delta-electroencephalogram (delta-sleep)-inducing peptide. Proceedings of the National Academy of Sciences, 1977.

• Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology, 1983.

• Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. European Neurology, 1984.

• Delta-sleep-inducing peptide (DSIP): a review. Neuroscience and Biobehavioral Reviews, 1984.

Cloud Aminos supplies DSIP as a high-purity research material intended strictly for controlled laboratory use in vitro or in established animal models. This compound is not approved as a drug, diagnostic or dietary ingredient and is not manufactured, packaged or marketed for human consumption, self-experimentation, clinical application or any use outside properly designed and ethically approved research protocols.